UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported):
| (Exact Name of Registrant as Specified in its Charter) |
| (State
or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(I.R.S.
Employer Identification Number) |
| (Address of Principal Executive Offices and Zip Code) |
| (Issuer’s telephone number) |
| (Former Name or Former Address, if Changed Since Last Report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| OTC Markets |
Item 1.01 Entry into a Material Definitive Agreement
On July 26, 2023, Therapeutic Solutions International, Inc., and Res Nova Bio, Inc., entered into an exclusive patent license agreement, included here in exhibit 10.1.
Item 8.01 Other Events.
The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference including reference to exhibits.
Item 9.01 Financial Statements and Exhibits.
| Exhibit Index | |
| (10.1) | Exclusive Patent License Agreement between Therapeutic Solutions International, Inc. and Res Nova Bio, Inc. |
| 104 | Cover Page Interactive Data File (Embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: July 26, 2023 | ||
| THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. | ||
| By: | /s/ Timothy Dixon | |
| Timothy Dixon | ||
| Chief Executive Officer | ||